Curevo Inc.

About Curevo

Clinical-stage biotech company developing next-generation adjuvanted subunit vaccines. Lead candidate amezosvatein targets shingles prevention with improved tolerability. Based in Bothell, WA; acquired by Eli Lilly in 2026.
Get insights on Curevo
with chemXplore Alpha

About Curevo on our platform

To provide comprehensive coverage, we aggregate data and news under the name Curevo, encompassing the following company names, divisions, and related entities:

Curevo Vaccine.

This list encompasses current and former names, alternate names, and key divisions associated with Curevo, ensuring you can easily find all relevant information under a single, unified profile.